Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Anal Cancer Metastatic × Gastrointestinal × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 401 Pancreatic Neoplasms 319 Stomach Neoplasms 219 Carcinoma, Hepatocellular 203 Carcinoma, Non-Small-Cell Lung 145 Colonic Neoplasms 129 Esophageal Neoplasms 122 Ovarian Neoplasms 99 Neoplasms 99 Rectal Neoplasms 94 Neoplasm Metastasis 88 Liver Neoplasms 87 Breast Neoplasms 87 Lung Neoplasms 67 Melanoma 66 Squamous Cell Carcinoma of Head and Neck 62 Carcinoma, Renal Cell 51 Gastrointestinal Neoplasms 49 Endometrial Neoplasms 48 Biliary Tract Neoplasms 47 Head and Neck Neoplasms 46 Uterine Cervical Neoplasms 45 Triple Negative Breast Neoplasms 42 Cholangiocarcinoma 42 Sarcoma 41 Prostatic Neoplasms 38 Esophageal Squamous Cell Carcinoma 36 Urinary Bladder Neoplasms 31 Carcinoma 27 Small Cell Lung Carcinoma 24

Interventions

trifluridine tipiracil drug combination 1 reolysin 1 atezolizumab 1 Gemcitabine 1 Albumin-Bound Paclitaxel 1 130-nm albumin-bound paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07280377 2025-12-12

GOBLET

Oncolytics Biotech

Phase 1/2 Recruiting

Gastrointestinal

Anal Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡